Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations
April 21 2020 - 8:17AM
Business Wire
Proven executive with clinical operations
expertise to guide Company’s clinical programs with gene
therapies
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
today announced the appointment of Shannon Inman as Vice President
of Global Clinical Operations. In this new position, Ms. Inman will
lead in defining clinical developmental strategies, clinical
protocol design, study conduct, and managing risk assessment. These
clinical trials include those with the Company's lead drug
candidate, Oncoprex™, for non-small cell lung cancer (NSCLC), which
recently received Fast Track Designation for its combination with
osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug
Tagrisso®.
"Genprex continues to strengthen its leadership team with the
appointment of an accomplished executive to drive the launch of key
clinical trials," said Rodney Varner, Chairman and Chief Executive
Officer of Genprex. "Ms. Inman brings a wealth of experience in the
pharmaceutical industry, having successfully directed a number of
development programs in both large and small biotechnology
companies and top tier academic institutions. She will be
instrumental in continuing to build the long-term value of our gene
therapies. With the addition of our second investigational gene
therapy asset addressing the unmet medical need of people suffering
from diabetes, I'm excited about building the necessary
infrastructure to facilitate our growth."
Prior to Genprex, Ms. Inman served in several clinical
operations positions, most recently as Vice President of Global
Clinical Operations at Cell Medica (now Kuur Therapeutics),
providing strategic and operational leadership for gene and cell
therapy clinical-stage programs, overseeing global clinical
operations teams and multi-center global clinical trials targeting
various oncology indications. Before that, Ms. Inman held positions
of increasing responsibility at Opexa Therapeutics, focusing on
T-cell therapies. She has also held various positions at Baylor
College of Medicine’s Center for Cell and Gene Therapy working in
regulatory, project management, and data management roles since the
department’s inception.
Ms. Inman received her Bachelors of Science at Texas A&M in
biomedical science. She is a Certified Clinical Research
Professional (CCRP), is involved in numerous professional
associations, and is a co-author of seven publications.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, Oncoprex™, is being evaluated as a treatment for
non-small cell lung cancer (NSCLC). Oncoprex has a multimodal
mechanism of action that has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells;
re-establish pathways for apoptosis, or programmed cell death, in
cancer cells; and modulate the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. In January 2020, the U.S. Food and Drug
Administration granted Fast Track Designation for Oncoprex
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®). For more information, please
visit the Company’s web site at www.genprex.com or follow Genprex
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding our
possible commercial partnerships and regarding our financial
resources. Risks that contribute to the uncertain nature of the
forward-looking statements include the presence and level of the
effect of our product candidates, alone and in combination with
other therapies, on cancer; the timing and success of our clinical
trials and planned clinical trials of Oncoprex™, alone and in
combination with targeted therapies and/or immunotherapies, and
whether our other potential product candidates, including our gene
therapy in diabetes, advance into clinical trials; our ability to
enter into strategic partnerships and the success of those
partnerships; the timing and success of obtaining FDA approval of
Oncoprex™ and our other potential product candidates; and the
extent and duration of the current and future economic and pandemic
related challenges we may face. These and other risks and
uncertainties are described more fully under the caption “Risk
Factors” and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005089/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024